SpringWorks Therapeutics Inc

NASDAQ:SWTXUnited States

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Contact Information

Headquarters

100 Washington BlvdSTAMFORD, CT, United States 06902-9302

Phone

203-883-9490

Fax

302-655-5049

Executives

Independent Chairman of the Board

Daniel Lynch

Chief Executive Officer, Director

Saqib Islam

Chief Financial Officer

Francis Perier

Chief Operating Officer

Badreddin Edris

Chief People Officer

Daniel Pichl